Sekisui XenoTech expands hepatotoxicity testing services

By Melissa Fassbender contact

- Last updated on GMT

Hepatotoxicity, or drug induced liver injury (DILI) is one of the leading causes of adverse events during clinical trials. (Image: iStock/eranicle)
Hepatotoxicity, or drug induced liver injury (DILI) is one of the leading causes of adverse events during clinical trials. (Image: iStock/eranicle)

Related tags: Clinical trial

The global contract research organization (CRO) is increasing its focus on hepatotoxicity, one of the leading causes of adverse events in clinical trials.

Sekisui XenoTech announced it has added supplementary hepatotoxicity screening assays and methodologies to its existing cytotoxicity contract research services.

According to the company, Hepatotoxicity, or drug induced liver injury (DILI) is one of the leading causes of adverse events during clinical trials and can lead to drug failures, clinical holds, or market withdrawals.

Matt Beck, Sekisui XenoTech’s Global Marketing Manager, told us the company has provided in vitro​ cytotoxicity screening services for many years, often as part of enzyme induction studies​. However, the company is increasing its focus on hepatotoxicity in order to protect its customer from costly drug candidate failures further down the development pipeline.

As Beck explained, "Discovering risks of liver injury during the preclinical stage of development, instead of clinical trials, can save hundreds of millions of dollars or more, and years of fruitless research​.”

Becky Campbell, Sekisui XenoTech’s Principle Scientist for Toxicology Research Services, told Outsourcing-Pharma.com, “[This is]not to mention potentially saving patient lives by discovering the potential for DILI early in development​.”.

However, early discovery of hepatotoxicity is challenging.

DILI observed in a clinical setting is often idiosyncratic with undefined mechanisms of toxicity and low incidence rates, even in large populationsdue to the increased number of drugs in medical care and the increased number of patients​,” said Campbell.

Yet, she explained that several mechanisms contributing to DILI have been well-characterized and have the potential to be tested in a non-clinical setting or with in vitro​ tools.

Campbell added that the addition of supplementary offerings “is a natural progression to add tools to our in vitro hepatocyte services that complement and expand our expertise​.

Our goal is to work with our clients’ project teams to design and guide an intelligent approach to the evaluation of hepatotoxicity with knowledge of mechanisms, ​in vitro tools and the application of various endpoints, combined to provide data suitable for decision making, whether during early-stage discovery or late-stage development​,” she said.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars